Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.

International journal of molecular sciences - 18 Mar 2018

Song Moo-Kon, Park Byeong-Bae, Uhm Ji-Eun

Abstract excerpt

Myelofibrosis (MF) is a clinical manifestation of chronic BCR-ABL1-negative chronic myeloproliferative neoplasms. Splenomegaly is one of the major clinical manifestations of MF and is directly linked to splenic extramedullary hematopoiesis (EMH). EMH is associated with abnormal trafficking patterns of clonal hematopoietic cells due to the dysregulated bone marrow (BM) microenvironment leading to progressive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bone Marrow
Share to Chemokine CXCL12
Share to Janus Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Primary Myelofibrosis

Share to Randomized Controlled Trials as Topic

Share to Receptors, CXCR4

Share to Spleen

Share to Splenomegaly

Source

Open in PubMed Open full text

Identifiers

PMID: 29562644
DOI: 10.3390/ijms19030898
PMCID: PMC5877759

Genes

ABL1
BCR
CALR
CXCL12
CXCR4
IDH1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.PMID 29562644Read ↗

Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and TreatmentsSemantic proximity Read ↗

Myelofibrosis: an update on current pharmacotherapy and future directions.Semantic proximity Read ↗

[Recent advances in the treatment of myelofibrosis].Semantic proximity Read ↗

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.Semantic proximity Read ↗

Targeted Therapies in Myelofibrosis: Present Landscape, Ongoing Studies, and Future Perspectives.Semantic proximity Read ↗

Primary Myelofibrosis: Update on Definition, Pathogenesis, and TreatmentSemantic proximity Read ↗

Recent advances in the diagnosis and management of primary myelofibrosis.Semantic proximity Read ↗

[Myelofibrosis: A review].Semantic proximity Read ↗

Biological drivers of clinical phenotype in myelofibrosis.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Is Combination Therapy Here for Myelofibrosis?Semantic proximity Read ↗

Myelofibrosis: challenges for preclinical models and emerging therapeutic targets.Semantic proximity Read ↗

Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.